- Trial phase
- Phase 1/2
- Time to market
- Unknown; currently in Phase 1 dose-finding, with Phase 2 advancement expected in 2026 at the earliest. Commercialization is likely several years away if successful.
- Why 2/10
- No hard dated binary catalyst in the next ~12 months. IOV-3001 is in early Phase 1 dose-escalation (IOV-IL2-101 trial); the next milestone is Phase 1 safety data and potential Phase 2 advancement, but no specific date is set. The drug is a supportive component of the TIL regimen, not the company's primary value driver, that is Amtagvi, which is already approved and commercialized.
IOV-3001 is too early-stage to drive meaningful stock movement in the near term. Iovance investors should focus on Amtagvi commercial execution, the Phase 3 TILVANCE-301 frontline melanoma readout, and catalysts from IOV-4001 and IOV-LUN-202 (NSCLC), all of which carry more weight for IOVA's share price than this early IL-2 analog program.
Price Chart
Executive Summary
IOV-3001 is Iovance Biotherapeutics' second-generation, modified IL-2 analog in Phase 1/2 development as a supportive regimen component for TIL therapy in advanced melanoma. Licensed from Novartis in 2020, the drug is designed to replace aldesleukin (the current standard IL-2 in TIL therapy) with a longer half-life and better safety profile. Preclinical data presented at ASCO 2024 was encouraging, and the Phase 1/2 trial (IOV-IL2-101) is actively enrolling with dose escalation ongoing as of Q1 2026. However, IOV-3001 is a relatively minor, early-stage pipeline asset for Iovance, the company's primary value driver is the already-approved Amtagvi (lifileucel), and IOV-3001 is just one of several next-generation pipeline candidates. No near-term binary catalyst exists for this drug.
How It Works
IOV-3001 is a redesigned version of interleukin-2 (IL-2), a natural immune-signaling protein that helps cancer-fighting T cells grow and survive. The standard IL-2 drug (aldesleukin) is inconvenient because it has a very short half-life, requiring doses every 8-12 hours, and causes harsh side effects. IOV-3001 fuses modified IL-2 to an antibody backbone, giving it a longer half-life (less frequent dosing) and a potentially safer side-effect profile. It is used as a supportive therapy after TIL (tumor-infiltrating lymphocyte) cell infusion to help the infused cells expand and persist in the patient's body.
Trial Status
Phase 1/2 open-label trial (IOV-IL2-101, NCT06940739) is actively enrolling patients with advanced melanoma. As of Q1 2026 (May 2026), the Phase 1 safety cohort is advancing through multiple dose levels. The Phase 1 portion has two parts: IOV-3001 given before lifileucel (Part 1) or after lifileucel replacing aldesleukin (Part 2). Estimated enrollment is ~42 patients. Preclinical data (presented at ASCO 2024) showed longer half-life and a favorable safety profile vs. aldesleukin.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 safety data readout from IOV-IL2-101 trial (no specific date yet; dose escalation ongoing as of May 2026)
- Advancement into Phase 2 portion of the trial (expected sometime in 2026 per company guidance)
- Potential presentation of early clinical data at medical conferences (e.g., ASCO, SITC)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report